



# Proteomics International

LABORATORIES LTD

ASX/Media Release

27 March 2020

ASX code: PIQ

## Issue of Corporate Advisory Options

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises that further to the ASX announcement of 25 November 2019, and following receipt of shareholder approval at the extraordinary general meeting held earlier today, a total of 3,040,279 options (**Corporate Advisory Options**) have been issued to nominees of Alto Capital and Adelaide Equity Partners.

Alto Capital acted as Lead Manager and Adelaide Equity Partners acted as Corporate Advisor to the placement which raised \$3.0 million from new and existing institutional, family office, sophisticated and professional investors.

The Corporate Advisory Options have an exercise price of \$0.50 per option and an expiry date of 27 March 2023.

An Appendix 3B will be lodged separately.

### Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Options noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) the Company issued the Options without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- (c) as at the date of this Notice, there is no information:
  - i. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
  - ii. that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
    - a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - b. the rights and liabilities attaching to the relevant Options.

This announcement was authorised to be given to ASX by the Board of Directors of Proteomics International Laboratories Ltd.

ENDS

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth’s QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
[Corporate Advisor & Investor Relations]  
Adelaide Equity Partners  
T: +61 8 8232 8800  
[E: dvandissel@adelaideequity.com.au](mailto:dvandissel@adelaideequity.com.au)